Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epidemiological studies  by Niculescu-Duvaz, I. et al.
Development of an outpatient finger-prick
glomerular filtration rate procedure suitable for
epidemiological studies
I Niculescu-Duvaz1,2, L D’Mello1,2, Z Maan1, JL Barron1, DJ Newman1, MEC Dockrell1 and JTC Kwan1
1South West Thames Institute for Renal Research, St Heller Hospital, Carshalton, Surrey, UK
Development of an outpatient finger-prick glomerular
filtration rate (GFR) procedure suitable for epidemiological
studies. In clinical practice, reference GFR procedures are
rarely used; in large-scale research studies, a great deal of
effort and experience is required to obtain them, which is a
considerable disincentive to using GFR as an end point. The
major problem for both clinical staff and the subject is the
length of time that the procedure takes, requiring continuous
attendance in the outpatient clinic or its vicinity. Using
iohexol as a marker, we therefore propose an alternative
approach, which addresses this fundamental deterrent to a
more widespread use of GFR measurement. Eighty-two GFR
measurements were performed in a mixture of healthy
subjects and patients with differing degrees of renal
impairment with a wide range of GFRs. Serum was obtained
from blood samples to enable a reference GFR to be
calculated. Blood spots were collected on filter paper at the
same intervals (120, 180, and 240 min), allowed to dry, and
then sent through the post. Serum and blood spots were
analyzed simultaneously for each individual by automated
reverse-phase high-pressure liquid chromatography.
Standard linear regression analyses confirmed a good
agreement (r2¼ 0.953) between the iohexol serum GFR and
iohexol blood spots GFR. Bland–Altman analysis confirmed
that there was no concentration bias. Paired comparisons
(Wilcoxon’s paired signed rank test) showed no significant
difference between the two measurements. Capillary
sampling is simple, effective, and significantly reduces the
time and costs of performing plasma clearance GFR
measurements. This approach will make the GFR
measurement more accessible for clinical practice and
large-scale epidemiological studies may become feasible.
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Early diagnosis of declining renal function facilitates inter-
vention to delay the onset of end-stage renal failure. To
diagnose renal disease, early and accurately precise diagnostic
tools are necessary. Glomerular filtration rate (GFR) is the
major test of renal function. The most effective measurement
of GFR is the measurement of inert substances exclusively
cleared from the body by glomerular filtration. Inulin
introduced in the 1930s1 is still often used as a reference
substance; however, this method is not widely available.2
Measurements of clearance of radiolabeled markers such as
51Cr-ethylenediamine tetraacetic acid are also widely used but
require specialized facilities, and repeated use of radioactivity
is undesirable and is not suitable for all patients.
In the 1980s, the development of rapid and reliable
measurements of the clearance of the non-ionic radiological
contrast agent iohexol was described. Subsequently, many
studies have validated the use of iohexol clearance as a
measure of GFR. Iohexol clearance was compared with Cr-
ethylenediamine tetraacetic acid clearance3 and inulin in
adults4 and children5 and was found to be almost identical.
Its low acute toxicity,6 easy handling, and stability recom-
mend iohexol clearance as a reference method. So much so
that it has been suggested that it may be a ‘new gold
standard’.4 GFR measurement using iohexol requires the
subject to remain in the clinic for up to 5 h for subsequent
blood sampling. This is time consuming and expensive and
makes such a process unrealistic for screening or large-scale
epidemiological studies. Therefore, in the present study, we
propose an outpatient finger-prick method for the determi-
nation of iohexol GFR, which is suitable for the clinical
practice and also for use in large-scale studies through
collection of capillary samples on filter paper.
RESULTS
In the subset of patients (n¼ 41) where posted blood spots
were compared with not posted blood spots, no significant
difference was observed, 67.174.9 vs 69.074.9 (mean GFR
(ml/min/1.73 m2)7s.e.m. for posted and not posted).
The analysis of blood spiked with 50mg/ml iohexol gave a
recovery of 50.471.4mg/ml in blood spots and 45.671.8mg/ml
in whole blood. Comparison of recovery from whole
blood was no different from recovery from plasma after
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hematocrit (ht) correction. Iohexol was stable for up to 4 h at
371C.
Precision
Analysis of plasma, plasma spots, and blood spots showed an
intra-assay mean coefficient of variance of 2.7, 3.5, and 4.3%,
respectively. The mean coefficient of variance for inter-assay
variability was 6.0% for plasma, 6.4% for plasma spots, and
5.3% for blood spots (Table 1).
Method comparison
Comparison of GFR measurements using serum and blood
spots by standard linear regression analysis confirmed a good
agreement between the two techniques (r2¼ 0.953), and
Bland–Altman analyses showed a bias of 1.17 with upper
and lower limits of agreements (bias72 s.d.) of 13.78
(confidence interval 16.52, 11.04) and 16.12 (confidence
interval 13.38, 18.86), respectively (Figure 1a and b).
DISCUSSION
Iohexol has been shown to be a safe and reliable reagent in
the measurement of GFR. However, it has required subjects
remaining in clinic for up to 5 h. This paper describes a
highly valuable alternative in the outpatient finger-prick
method for the determination of iohexol GFR.
Validation experiments performed confirmed the feasi-
bility of this method; no differences were seen whether the
samples were posted or not; and recovery experiments demon-
strated a near 100% recovery of iohexol from blood spot
samples; furthermore, no difference was observed between
recovery from blood and ht-corrected plasma, indicating
minimal association of iohexol with blood cells. Both intra-
and inter-assay variability was acceptable. Comparison of the
serum iohexol GFR with blood spots GFR concluded that
there was no significant difference between the two and there
was no concentration-dependent bias in the correlation.
Blood spot analysis will also help facilitate the use of
iohexol GFR in small children, where heel prick can be used.
The standard assessment of a percutaneous central venous
catheter involves the injection of 1–2 ml of iohexol before
taking a radiograph of a baby’s chest, so that a GFR can be
additionally performed. Blood collection from some renal
patients is often more difficult owing to repeated venipunc-
ture. The use of small volumes for blood spots may also be of
use in these patients.
There are certain issues that need to be addressed before
the system can be used as an ‘outpatient’ device, where the
subject is responsible for taking the blood samples. First is the
actual finger-prick method. In this study, blood was taken by
a trained member of the staff; however, it is envisaged that
the subjects should be able to do this and this is currently
being trialed. Currently, spring-loaded lancets are used;
however, a patent has been submitted for ‘finger-grip’ that
holds the finger and lancet in place, allowing the whole
procedure to be performed with greater ease. The timing of
samples is an important issue in the measurement of GFR
using iohexol. Blood was taken at 2, 3, and 4 h, and although
the timing does not have to be accurate, the precise time does
need to be recorded. Consequently, a small disposable timing
device has also been developed, which was activated when
iohexol was administered and again when the blood sample
was taken, and was then returned to the laboratory with the
sample. The ‘finger-grip’ and timer together would form a
compact and inexpensive tool to allow this methodology to
be used more widely.
There are conflicting data concerning how many time
points are required for precise iohexol GFR measure-
ments.7–10 Consequently, in this study, comparison was made
using three time points in both serum and blood spots.
Table 1 | Intra- and inter-assay variability of plasma and
plasma spot assay
Concentration iohexol (lg/ml) 20.2 40.4 80.8 Mean
Intra-assay cv (%)
Plasma, n=10 3.4 0.3 4.2 2.7
Plasma spot, n=10 3.3 3.8 3.5 3.5
Inter-assay cv (%)
Plasma, n=14 6.3 6.2 5.6 6.0
Plasma spot, n=10 8.1 6.2 4.8 6.4
Intra-assay cv (%)
Blood spots, n=6 3.6 6.7 2.6 4.3
Inter-assay cv (%)
Blood spots, n=10 5.1 6.1 4.8 5.3
cv, coefficient of variance.
y = 1.0238x – 0.0764
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Figure 1 | Accuracy of blood spot GFR relative to serum GFR.
(a) Correlation between iohexol serum GFR and blood spots GFR
(ml/min/1.73 m2) calculated according to single-compartment ana-
lyses and corrected by the Brochner-Mortensen equation. (b) Analysis
by Bland–Altman plot demonstrates that the difference between the
two measurements (y axis), finger prick and serum showed a bias of
1.17, which did not significantly change with changes in the degree
of GFR (x axis).
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Precision of less time points would require further study and
comparison with formula-determined GFR.
In conclusion, the development and validation of a blood
spot outpatient finger-prick method for the determination of
iohexol GFR will improve GFR measurements in some
patient groups and facilitate the epidemiological studies and
screening projects, which will improve the detection of renal
disease and our understanding of its distribution in the
population.
MATERIALS AND METHODS
After obtaining informed consent, 22 healthy volunteers and 60
patient volunteers were included. The median age of all healthy
volunteers (9 men and 13 women) was 41 years (range 21–62 years)
and had levels of serum creatinine within the laboratory reference
range. The patients (with differing degrees of renal impairment and
a wide range of GFR-S) volunteering for the study (34 men and 26
women) were selected on the basis of serum creatinine with:
‘normal’ (o130 mmol/l; n¼ 56 mean creatinine 96 mmol/l), medium
(130–300mmol/l; n¼ 21 mean creatinine 170mmol/l), and high
(4300 mmol/l; n¼ 11 mean creatinine 479mmol/l) levels of serum
creatinine. Creatinine was measured by a routine Bayer kit using the
O’Leary modified kinetic Jaffe method on Bayer Advia 1650
equipment. Clearance was adjusted to the body surface calculated
according to Du Bois and Du Bois11 at 1.73 m2.
Patients had a restricted diet (low protein intake and non-
caffeinated drinks) for approximately 6 h before the test. Height and
weight were recorded.
A zero-time blood sample was collected into BD Vacutainer SST
II Advance tubes and an additional blood sample collected into
ethylenediamine tetraacetic acid (for ht analyses) was collected
before the intravenous injection of 5 ml of iohexol (Omnipaque 300,
Nycomed Amersham Plc, Buckinghamshire, UK) and the exact time
of the injection was recorded. The cannula was flushed with 10 ml of
0.9% saline. After the injection of contrast media, blood samples
were collected into BD Vacutainer SST II Advance tubes at
approximately 120, 180, and 240 min by separate venipuncture of
the antecubital vein from the contralateral arm in which the
iohexol was injected. The exact collection time was recorded. Blood
spots were collected by finger-prick, taken by a member of staff, on
the filter paper (Schleicher and Schuell Grade 903) at the same
intervals as the blood samples and the exact collection time was
recorded. Serum was separated from the blood samples and stored at
201C.
Patients were supervised for 15 min for possible adverse reactions
and then they were allowed to leave the department between
sampling.
In a subset of 41 subjects, two sets of blood spots were analyzed.
One set of spots was posted and one not posted. Both samples were
analyzed at the same time. Ethical approval was given by Merton
and Sutton Local Research Ethics Committee, number 71/00.
Iohexol standards and quality controls
Iohexol stock solution (647 mg/ml) was diluted into mobile phase
(acetonitrile 3.5% pH adjusted to 2.5 with concentrated orthopho-
sphoric acid) to give final concentrations of 0, 129, and 294mg/ml
iohexol and stored at 41C.
Iohexol stock solution was diluted in serum to give quality
controls with concentrations of 20.2, 40.4, and 80.8mg/ml and
stored at 701C.
Samples analyses
Fifty-six microliters of serum samples, standards, and quality
controls were treated with 850 ml of 5% perchloric acid to precipitate
serum proteins. For blood spots, a 6.3 mm diameter punch of the
blood spot (containing 11.2ml of blood) was treated with 170 ml 5%
perchloric acid. Samples were vortexed for 3 min, ultrasonicated for
15 min, incubated for 30 min on the bench at room temperature,
and then spun at 14 000 g for 10 min. The volume of one injection
for both serum and spots was 100ml.
High-pressure liquid chromatography analyses
Iohexol was quantitated from serum and spots by automated reverse
phase high-pressure liquid chromatography detector (Tosoh TSK
6040; pump-Laserchrom, Rochester, Kent UK; autosampler-Waters
717) using external calibration column—Nucleosil 120; C18; 5 mm;
20 4.6 mm—and guard column-Nucleosil 120 5 0.46 mm—
Jones Chromatography (Hengoed, UK), maintained at 301C, pump
1.5 ml/min, detector-wavelength 254 nm, and range 0.05. The
second peak, which elutes at 7.5 min, was used for the calculation
of the GFR (ml/min/1.73 m2).
Method optimization
To determine recovery of iohexol and to investigate red blood cell
uptake, blood from subjects was collected, spiked with iohexol
(50mg/ml), and recovery was compared between serum analyzed
directly and blood spotted onto filter paper. Furthermore blood was
spiked with 50 mg/ml iohexol and incubated for 0, 1, 2, 3, and 4 h at
371C. Plasma was prepared from a separate aliquot of blood and
recovery of iohexol was compared between blood and plasma,
corrected for ht.
Precision. Plasma was spiked with 20.2, 40.4, and 80.8 mg/ml
iohexol. Plasma was both analyzed directly and spotted on to paper.
Analysis of intra- and inter-assay variation was investigated in both
plasma and plasma spots.
Calculations of GFR
Blood spot iohexol concentrations were calculated assuming a fixed
volume of blood on the filter paper. The equivalent value for serum
is then calculated using the ht correction formula (iohexol)/(1ht).
An analysis was performed as described previously.3 In brief,
single-compartment analyses equation 1 with Brochner-Mortensen
correction was performed with three blood samples taken over a 4 h
period.12
Clearance (Cl1) according to one-compartment model was
calculated from the least mean square semilog curve fit giving the
elimination constant (k) and y-intercept (C0) of the fitted line:
Cl1 ¼ Dose=ðC0=kÞ
The Brochner-Mortensen correction gives greater accuracy
Clp ¼ 0:990778Cl1  0:001218Cl21
This final clearance was corrected for 1.73 m2 standardized body
surface area.
Statistical analyses. Standard linear regression was used to
compare the two techniques. Results were analyzed by paired
comparisons (Wilcoxon’s paired signed rank test) and Bland–Altman
analyses.
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